Background {#Sec1}
==========

Acute respiratory distress syndrome (ARDS) comprises heterogenous clinical conditions. Reportedly, the prognosis of ARDS is poor \[[@CR1], [@CR2]\], and once a patient develops ARDS, treatment options are limited to only a few supportive strategies \[[@CR3]--[@CR9]\], making it important to identify patients at a high risk of ARDS \[[@CR10]\]. Previous studies have reported a variety of causes and risk factors of ARDS \[[@CR1], [@CR11]\]; however, there is a lack of clarity between these because only a small proportion of patients with these causes and risk factors develop ARDS \[[@CR12], [@CR13]\]. Therefore, alternative efforts have been recently focusing on the roles of two types of risk factors: predisposing conditions and risk modifiers \[[@CR14], [@CR15]\]. Predisposing conditions are preceding acute pathophysiological events, such as sepsis. Risk modifiers include obesity \[[@CR15], [@CR16]\], smoking status \[[@CR15], [@CR17], [@CR18]\], diabetes mellitus (DM) (reduced risk modifier) \[[@CR14], [@CR15], [@CR19]\], glucocorticoids \[[@CR20]\], statin \[[@CR21], [@CR22]\], non-pulmonary infection (reduced risk modifier) \[[@CR13], [@CR23]\], shock \[[@CR13], [@CR15]\], tachypnea \[[@CR14], [@CR15]\], oxygen supplementation \[[@CR15], [@CR24]\], hematocrit \[[@CR11]\], hypoalbuminemia \[[@CR14], [@CR15]\], acidemia \[[@CR11], [@CR15]\], and disease severity \[[@CR2], [@CR11], [@CR13]\]. There is a possibility that ARDS may be precisely predicted using a combination of predisposing conditions and risk modifiers.

ARDS has been associated with two major pathophysiologic changes in various proportions. One is the influx of protein-rich effusion to the alveolar space caused by the damage of the local alveolar epithelium and another is leakage to the pulmonary interstitium through the capillary endothelium caused by systemic inflammation. Direct ARDS is associated with higher impairment of alveolar epithelium and lower impairment of capillary endothelium than indirect ARDS \[[@CR23], [@CR25]\]. Thus, we think risk modifiers of direct and indirect ARDS should be discussed separately.

Indeed to date, however, little has been reported about risk modifiers for ARDS among patients with non-pulmonary sepsis because a large proportion of patients with pulmonary sepsis have been included in previous studies about risk modifiers \[[@CR2], [@CR14], [@CR15]\].

We aimed to evaluate the risk modifiers associated with indirect ARDS among patients with non-pulmonary sepsis.

Methods {#Sec2}
=======

Design and setting {#Sec3}
------------------

We conducted a secondary analysis of the sepsis cohort in the Focused Outcomes Research in Emergency Care in Acute Respiratory Distress Syndrome, Sepsis, and Trauma (FORECAST) study. This was a multicenter prospective cohort study of 1184 patients with severe sepsis or septic shock enrolled from 59 Intensive care units (ICUs) in Japan and conducted from January 2016 to March 2017 \[[@CR26]\].

Participants {#Sec4}
------------

We included adult patients from the FORECAST database if they were aged ≥ 16 years and had severe sepsis or septic shock caused by non-pulmonary infection. The exclusion criteria were patients with missing data of the first or fourth days of ARDS screening in this study.

Data collection {#Sec5}
---------------

Patient information was obtained from the FORECAST database, including demographic data, admission source, comorbidities, infection sites, sepsis-related severity scores, and laboratory data. Data collection was performed as part of the routine clinical workup by the original FORECAST investigators.

Data definitions {#Sec6}
----------------

ARDS was diagnosed if present on the first or fourth day of ARDS screening, according to the Berlin ARDS definition \[[@CR27]\]. Severe sepsis and septic shock were defined based on the sepsis-2 criteria \[[@CR28]\]. Non-pulmonary infection was defined as infection other than pneumonia or empyema. Cases of DM with and without end-organ complications were reported as comorbidities. Also, "ventilator-free days" was defined as the number of days within the first 28 days after enrolment, during which a patient was able to breathe without the help of a ventilator. Patients who died during the study were assigned a ventilator-free day of 0. ICU-free days were calculated and scored in a similar manner \[[@CR29]\].

Statistical analysis {#Sec7}
--------------------

Patients were stratified into groups with and without ARDS (i.e., ARDS and No ARDS groups). Descriptive statistics were calculated as proportions for categorical variables and as medians (interquartile range \[IQR\]) or mean ± standard deviation (SD) for continuous variables, where appropriate. Statistical differences between two groups were evaluated by univariate analyses, using the chi-square or Fisher exact tests for categorical variables and the Mann--Whitney *U* test for continuous variables because the data did not have a normal distribution.

To identify the risk modifiers correlated with having ARDS in patients with non-pulmonary sepsis, we developed a multivariate logistic regression model and reported odds ratios (ORs) with their 95% confidence intervals (CIs). We hypothesized that there could be different risk modifiers for indirect ARDS compared with those for direct ARDS reported in previous studies. The primary outcome of interest was having ARDS, and the explanatory variables were selected based on previous research: body mass index, smoking status, DM, glucocorticoids, statin, site of infection, septic shock, and acute physiology and chronic health evaluation II (APACHE II) score. We also include clinically relevant explanatory variables, such as age, gender, admission source, and coexisting conditions (e.g., congestive heart failure and chronic obstructive pulmonary disease). However, we did not take variables such as tachypnea, oxygen supplementation, acidosis, and hypoalbuminemia into the logistic regression model because these possible risk modifiers might result from ARDS. Finally, the non-pulmonary Sequential Organ Failure Assessment (SOFA) score was used in a sensitivity analysis.

All *p* values were two-sided, with *p* values \< 0.05 considered statistically significant. All statistical analyses were performed using the EZR software (Version 1.32) \[[@CR30]\].

Results {#Sec8}
=======

Of the 1184 patients with severe sepsis in the FORECAST study, 817 with non-pulmonary infection were eligible for this study. Another 85 patients were excluded because they had missing data of the first day of ARDS screening. This left a cohort of 69 patients with ARDS and 663 without ARDS on the first day of screening. Of those without ARDS, 35 died on the second or third day and 103 patients had missing data of the fourth day of ARDS screening, so were excluded. Finally, 594 patients with non-pulmonary sepsis were enrolled, among whom 85 (14.3%) had ARDS at the first or fourth day of ARDS screening (the ARDS group) (Fig. [1](#Fig1){ref-type="fig"}) Fig. 1Flow of patient screening and enrolment ICU intensive care unit, ARDS acute respiratory distress syndrome.

Baseline characteristics {#Sec9}
------------------------

The median age was 72 (IQR: 62--81) years and males accounted for 340 patients (57.2%). There were 231 patients (38.9%) with abdominal infection, 147 (24.7%) with urinary tract infection, and 91 (15.3%) with soft tissue infection. The baseline characteristics are compared between patients with and without ARDS in Table [1](#Tab1){ref-type="table"}. Table 1Demographic, infection, and admission characteristics comparing those had ARDS and those did notCharacteristicsARDS (*n* = 85)No ARDS (*n* = 509)*P* valueAge at admission---year70 (62--80)72 (63--82)0.46Male gender51 (60)289 (56.8)0.66Admission sourceHospital wards and other hospitals28 (32.9)226 (44.5)0.12Emergency department52 (61.2)255 (50.2)Intensive care unit5 (5.9)27 (5.3)Body mass index---kg/m^2^23.4 ± 4.8223.4 ± 5.450.07Coexisting conditionsMyocardial infarction5 (5.9)27 (5.3)0.80Congestive heart failure9 (10.6)53 (10.4)1.00Peripheral vascular disease2 (2.4)10 (2)0.69Cerebrovascular disease7 (8.2)65 (12.8)0.31Dementia4 (4.7)44 (8.6)0.28COPD4 (4.7)25 (4.9)1.00Connective tissue disease5 (5.9)32 (6.3)1.00Peptic ulcer disease2 (2.4)17 (3.3)1.00Diabetes mellitus21 (24.7)121 (23.8)0.96Chronic kidney disease5 (5.9)39 (7.7)0.66Hemiplegia2 (2.4)20 (3.9)0.76Malignancy (solid)6 (7.1)68 (13.4)0.15Malignancy (blood)1 (1.2)9 (1.8)1.00Metastatic tumor2 (2.4)15 (2.9)1.00Mild liver disease3 (3.5)25 (4.9)0.78Moderate to severe liver disease0 (0)15 (2.9)0.15AIDS0 (0)1 (0.2)1.00CCI w/o diabetes mellitus0 (0--1)1 (0--2)0.004SmokingNever55 (66.3)275 (59.0)0.05Former24 (28.9)123 (26.4)Current4 (4.8)68 (14.6)Regular medicationGlucocorticoids9 (10.6)69 (13.6)0.56Immunosuppressants3 (3.5)21 (4.1)1.00Anticoagulant13 (15.3)42 (8.3)0.04Antiplatelet14 (16.5)87 (17.1)1.00Statin5 (5.9)53 (10.4)0.24Beta blocker5 (5.9)36 (7.1)0.82Anticancer drug2 (2.4)15 (2.9)1.00Antibiotics16 (18.8)70 (13.8)0.29Site of infectionAbdomen32 (37.6)199 (39.1)0.25Urinary tract15 (17.6)132 (25.9)Soft tissue17 (20.0)74 (14.5)Other than abdomen, urinary tract, or soft tissue21 (24.7)104 (20.4)Septic shock68 (80)336 (66)0.02Respiratory rate---/min25 (22--32)24 (21--30)0.34FiO~2~0.4 (0.3--0.5)0.3 (0.25--0.4)\< 0.001PaO~2~---mmHg83 (75--103)94 (78.6--112)0.05PaO~2~/FiO~2~ ratio179 (119--240)284 (184--374)\< 0.001Hematocrit---%33 (28--38)33 (29--39)0.38Serum albumin---g/dL2.4 (2.0--2.8)2.6 (2.2--3.2)0.01Blood pH7.36 (7.29--7.44)7.41 (7.34--7.47)0.003Positive blood culture54 (63.5)303 (59.9)0.53Pathogens (blood culture)Gram positive coccus23 (27.1)116 (22.8)0.39Gram negative rod28 (32.9)167 (32.8)0.98APACHE II score26 (21--33)21 (16--28)\< 0.001Non-pulmonary SOFA score9 (7--11)7 (4--9)\< 0.001Reported counts (proportions) for categorical variables and median (interquartile range) for continuous variables*ARDS* acute respiratory distress syndrome defined by Berlin criteria, *COPD* chronic obstructive pulmonary disease, *AIDS* acquired immune deficiency syndrome, *CCI* Charlson Comorbidity Index, *FiO*~2~ fraction of inspiratory oxygen, *PaO*~2~ partial pressure of oxygen in arterial blood, *APACHE II* acute physiology and chronic health evaluation II, *SOFA* sequential organ failure assessmentDefinition of categorical variables: other than abdomen, urinary tract, or soft tissue = central nervous system, intravenous catheter, osteoarticular, endocardium, wound, implant device, and others; positive blood culture = culture without clinically confirmed contamination; Gram-positive coccus = *Staphylococcus*, *Streptococcus*, and *Enterococcus*; Gram-negative rod = *Acinetobacter*, *Aeromonas*, *Burkholderia*, *Citrobacter*, *Escherichia*, *Enterobacter*, *Haemophilus*, *Klebsiella*, *Legionella*, *Pseudomonas*, *Proteus*, *Salmonella*, *Serratia*, *Stenotrophomonas*, and *Vibrio*Missing data (due to missing data of each outcome measures): admission source = 1; body mass index = 9; smoking = 45; respiratory rate = 1; FiO~2~ = 14; PaO~2~ = 18; PaO~2~/FiO~2~ ratio = 19; serum albumin = 10; blood pH = 14; positive blood culture = 3; APACHE II score = 53; non-pulmonary SOFA score = 46

Patients with ARDS had a lower Charlson Comorbidity Index than patients without ARDS, but there were no significant differences between the groups regarding other baseline characteristics, such as age, gender, and admission source. There was no significant difference between patients with and without ARDS regarding previously known risk modifiers for direct and indirect ARDS, including body mass index, DM, smoking status, and site of infection. A higher proportion of patients had septic shock with ARDS (80%) than without ARDS (66%; *p* = 0.02). Compared to those without ARDS, patients with ARDS had higher severity scores assessed by the APACHE II (26 vs. 21, *p* \< 0.001) and Non-pulmonary SOFA (9 vs. 7, *p* \< 0.001).

Outcomes in patients with ARDS {#Sec10}
------------------------------

In-hospital mortality in patients with and without ARDS was 29.9% and 16.5%, respectively (*p* = 0.007) (Table [2](#Tab2){ref-type="table"}). Of the 404 patients with septic shock, the in-hospital mortality rate of those with ARDS was significantly higher than that of patients without ARDS (32.8% vs. 17.9%, *p* = 0.01). The median ventilator-free days for patients with ARDS was less than that for patients without ARDS (15 \[0--21\] vs. 22 \[9--28\], *p* \< 0.001), as was the median ICU-free days (14 \[4--19\] vs. 19 \[10--24\], *p* \< 0.001). However, there was no significant difference in the length of hospital stay by ARDS status (25 \[11--61\] vs. 26 \[15--51\], *p* = 0.39). In terms of survivor dispositions, a larger proportion of patients with ARDS than without ARDS needed to be transferred to other facilities. Table 2Outcomes comparing patients with and without ARDS among patients with non-pulmonary sepsisVariableARDS (*n* = 85)No ARDS (*n* = 509)*P* valueIn-hospital mortality23 (29.9)84 (16.5)0.007with septic shock (*n* = 404)20 (32.8)60 (17.9)0.01Without septic shock (*n* = 190)3 (18.8)24 (13.9)0.71Survivor dispositions(*n* = 479)Home10 (18.5)157 (36.9)0.006Transfer44 (81.5)268 (63.1)ICU-free days14 (3.75--19.25)19 (10--24)\< 0.001Ventilator-free days15 (0--21)22 (8.75--28)\< 0.001Length of hospital stay25 (11--61)26 (15--51)0.35Reported counts (proportions) for categorical variables and median (interquartile range) for continuous variables*ARDS* acute respiratory distress syndrome, *ICU* intensive care unitMissing data (due to missing data of each outcome measures): in-hospital mortality = 8; survivor dispositions = 0; ICU-free days = 89; ventilator-free days = 9; length of hospital stay = 8

Risk modifiers for having ARDS {#Sec11}
------------------------------

In the multivariate logistic regression model, we identified three main risk modifiers associated with having ARDS (Table [3](#Tab3){ref-type="table"}). Notably, the odds of having ARDS were higher for patients from the emergency department than for those transferred from hospital wards or other hospitals (OR, 1.89 \[1.06--3.40\]), for patients with soft tissue infection than for those with abdominal infection (OR, 2.37 \[1.04--5.40\]), and for those with a higher APACHE II score (OR, 1.08 \[1.05--1.12\]). Table 3Multivariable analysis for having ARDS associated with non-pulmonary sepsis (*n* = 594)VariableOdds ratio (95% CI)*P* valueAge at admission---per year0.99 (0.97--1.01)0.29Male gender1.33 (0.71--2.49)0.37Admission sourceHospital wards and other hospitalsReferenceEmergency department1.89 (1.06--3.40)0.03Intensive care unit0.96 (0.25--3.65)0.95Body mass index---kg/m^2^1.04 (0.98--1.09)0.19SmokingNeverReferenceFormer0.77 (0.39--1.54)0.46Current0.18 (0.06--0.59)0.004Coexisting conditionsCongestive heart failure0.72 (0.26--1.88)0.50COPD1.54 (0.46--5.21)0.49Diabetes mellitus0.69 (0.35--1.37)0.29Regular medicationGlucocorticoids0.48 (0.19--1.22)0.12Statin0.36 (0.10--1.24)0.11Site of infectionAbdomenReferenceUrinary tract0.71 (0.33--1.55)0.39Soft tissue2.37 (1.04--5.40)0.04Other than abdomen, urinary tract, or soft tissue1.57 (0.74--3.32)0.24Septic shock1.43 (0.74--2.78)0.29APACHE II score---per point1.08 (1.05--1.12)\< 0.001*ARDS* acute respiratory distress syndrome, *CI* confidence interval, *COPD* chronic obstructive pulmonary disease, *APACHE II* acute physiology and chronic health evaluation IIDefinition of categorical variables: other than abdomen, urinary tract, or soft tissue = central nervous system, intravenous catheter, osteoarticular, endocardium, wound, implant device, and othersMissing data (due to missing data of each outcome measures): admission source = 1; body mass index = 9; smoking = 45; APACHE II score = 53

Discussion {#Sec12}
==========

In this retrospective cohort study of patients with non-pulmonary sepsis, admission route (from the emergency department rather than wards or other hospitals), disease severity (a higher APACHE II score), and infection site (soft tissue rather than abdominal infection) were risk modifiers for non-pulmonary septic ARDS. However, obesity, DM, statins, glucocorticoids, and shock were not statistically associated with ARDS.

Duration of onset from infection could be a valid risk modifier of ARDS in non-pulmonary sepsis. In our results, admission from the emergency department was related to having ARDS, and it is possible that both direct and indirect ARDS developed soon after or at the onset of sepsis \[[@CR15], [@CR31]\]. Thus, ARDS may not have occurred after time had passed from admission, and further studies are needed to investigate the timing of the onset of ARDS in non-pulmonary sepsis.

Site of infection also appeared to be a risk modifier for ARDS in non-pulmonary sepsis. One study showed that abdominal infection was related to with ARDS \[[@CR23]\], and another study showed that soft tissue infection was related to without ARDS in population that included pulmonary infection \[[@CR13], [@CR32]\]. The correlation with indirect ARDS in most previous studies may have been attenuated because pulmonary infection is a major predisposing condition and few studies focused on non-pulmonary infection \[[@CR2], [@CR14], [@CR15]\]. We showed that, when excluding this, soft tissue infection could be related to having ARDS. Not only pulmonary but also severe soft tissue infection could be a novel risk modifier. However, these patients were more likely to be admitted to wards instead of ICUs, presumably because shock was less common \[[@CR33]\]. By limiting our cohort to ICUs, we may have introduced some bias. It is possible that our data for site of infection reflect only disease severity, despite controlling for severity using the APACHE II score and shock status. Pathogens beyond the site of infection may also be related to having ARDS, but our sensitivity analysis did not show a difference (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Further studies are needed to confirm which infection site is more related to developing ARDS in patients with non-pulmonary sepsis.

We confirmed that the severity of non-pulmonary sepsis (APACHE II score) was related to having ARDS, consistent with the results in previous studies \[[@CR2], [@CR11], [@CR13]\]. In this study, we did not exclude the possibility of the pulmonary parameter of the APACHE II score representing pre-existing ARDS in the emergency department. Thus, we performed a sensitivity analysis by changing the APACHE II score with the non-pulmonary SOFA score, and it showed similar results to the main analysis (Additional file [1](#MOESM1){ref-type="media"}: Table S2). However, having shock was not related to having ARDS in our population, indicating that having ARDS in non-pulmonary sepsis might be associated with the development of multiple organ failure instead of circulatory failure (shock) \[[@CR2], [@CR31]\]. Further studies are needed to determine organ failures that are more likely to occur with ARDS.

We did not show roles for obesity, DM, statins, and glucocorticoids which have been shown to be risk modifiers for ARDS in previous studies. Although they were risk modifiers in direct and indirect ARDS combined, the tendencies of the ORs were similar. Otherwise, obesity may not be a risk modifier of ARDS due to non-pulmonary sepsis because of mechanism is not the same \[[@CR23], [@CR25]\]. DM, statin use, and glucocorticoid use have been protective against ARDS in some clinical and basic research \[[@CR20], [@CR21], [@CR34]\], but this has not been carried through to randomized clinical trials \[[@CR35]--[@CR37]\] and we found no benefits associated with the regular use of these medications. However, it is perhaps the lack of significance for the roles of obesity and smoking that was most unexpected.

Obesity is considered a risk modifier for ARDS because patients with obesity need higher tidal volumes, positive end-expiratory pressures, and sufficiently high peak airway pressures to counter the pressure of their chest wall and abdomen \[[@CR16], [@CR38]\]. The lack of difference in this study may reflect our small sample size.

Smoking has also been clearly linked as a direct risk modifier in clinical studies \[[@CR17], [@CR18]\], which is known to occur through direct damage to the alveolar epithelium that leads to local inflammation \[[@CR39], [@CR40]\]. Despite this, our results did not support it even indirectly, and we consider there to be two main reasons. First, smoking history may have been difficult to assess in critically ill patients. Including a combination of smoking-related biomarkers might have identified more current smokers than the smoking history obtained from patients, surrogates, and medical records \[[@CR41]\]. Second, unrecorded medication histories, including the use of inhaled corticosteroids and inhaled beta agonist may have been a confounding factor \[[@CR42]\]. It is conceivable that smoking and indirect ARDS are not associated, as is the case with smoking and direct ARDS \[[@CR23], [@CR25]\]. Since it is difficult to consider smoking as a protective factor, we only used smoking as an adjustment factor in this study.

Risk modifiers for ARDS among patients with non-pulmonary sepsis were similar to those reported for patients with direct and indirect ARDS in previous studies, but they were not the same. This information may help clinicians and researchers. For clinicians, it is important to carefully treat non-pulmonary sepsis particularly in patients with risk modifiers that we have shown. For researchers, it may help to develop future study design and may provide more research on which to assess risks. We recommend that more classifications or adjustments are needed for ARDS because of the large heterogeneity in the syndrome.

Limitations {#Sec13}
-----------

Several limitations of this study need to be acknowledged. First, we did not capture all ARDS episodes because we only performed screening on the first or fourth day. However, Most ARDS develops within 4 days of admission \[[@CR2], [@CR11], [@CR15]\] and most cases occur within 12 h if sepsis is a predisposing condition \[[@CR43]\]. Second, we only included patients in ICUs, although it should be noted that most cases would have been admitted to ICUs anyway \[[@CR2]\]. Third, there could be some unmeasured confounders because of the post hoc analysis, despite using mostly the same factors as in previous studies \[[@CR2], [@CR11], [@CR13]\]. Fourth, we diagnosed ARDS based on the application of the Berlin criteria by the physician in charge. Because the diagnosis of ARDS is difficult \[[@CR44]\], some cases might not have been diagnosed correctly, even if they had respiratory failure. Fifth, we assessed risk modifiers at the first day of registration, yet we know that the value of some factors might be related to timing. However, risk modifier candidates were limited to patient backgrounds and characteristics, which were fixed at data collection. Sixth, based on the results of power analysis, the sample size of this study may not have been enough for the assessment of smoking and BMI as risk modifiers. Finally, our cohort was limited to Japan \[[@CR2], [@CR11], [@CR13]\], and important geographic variations may have been missed \[[@CR45]\].

Conclusions {#Sec14}
===========

Our retrospective cohort study from the Japanese sepsis registry revealed that admission route, severity, and infection site could be risk modifiers for ARDS in patients with non-pulmonary sepsis.
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**Additional file 1: Table S1.** Multivariable analysis including pathogens. **Table S2.** Multivariable analysis including Non-pulmonary SOFA score instead of APACHE II score. Two supplementary tables contain the results of sensitivity analyses indicated in the main manuscript.
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